MIF -173G/C polymorphism is associated with NMO disease severity.


Journal

Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498

Informations de publication

Date de publication:
15 02 2020
Historique:
received: 25 09 2019
revised: 15 11 2019
accepted: 25 11 2019
pubmed: 4 12 2019
medline: 10 7 2020
entrez: 3 12 2019
Statut: ppublish

Résumé

Our knowledge about genetic factors that drive the worsening of neuromyelitis optica (NMO) is limited. Herein, we analyzed the macrophage migration inhibitory factor (MIF) -173G/C functional polymorphism in NMO patients and controls. Our data reveal that the frequency of the high-expression MIF genotypes (CC/GC) did not differ between the two groups. However, frequency of this genotypes was elevated in patients diagnosed with both optic neuritis and myelitis compared with patients that were diagnosed with only one symptom. Furthermore, patients carrying the CC/CG genotypes had significantly higher disability score. We conclude that MIF is associated with NMO severity rather than susceptibility.

Identifiants

pubmed: 31790982
pii: S0165-5728(19)30503-X
doi: 10.1016/j.jneuroim.2019.577120
pii:
doi:

Substances chimiques

Macrophage Migration-Inhibitory Factors 0
Intramolecular Oxidoreductases EC 5.3.-
MIF protein, human EC 5.3.2.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

577120

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Livnat Brill (L)

Department of Neurology and Laboratory of Neuroimmunology, and the Agnes-Ginges Center for Neurogenetics, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Israel.

Adi Vaknin-Dembinsky (A)

Department of Neurology and Laboratory of Neuroimmunology, and the Agnes-Ginges Center for Neurogenetics, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Israel.

Omri Zveik (O)

Department of Neurology and Laboratory of Neuroimmunology, and the Agnes-Ginges Center for Neurogenetics, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Israel.

Nitsan Haham (N)

Department of Neurology and Laboratory of Neuroimmunology, and the Agnes-Ginges Center for Neurogenetics, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Israel.

Keren Miller (K)

Tissue Typing and Immunogenetics Laboratory, Department of Genetics, Hadassah Medical Center, Jerusalem, Israel.

Gil Benedek (G)

Tissue Typing and Immunogenetics Laboratory, Department of Genetics, Hadassah Medical Center, Jerusalem, Israel. Electronic address: gilb@hadassah.org.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH